United Therapeutics Corporation (NASDAQ:UTHR) was the target of a large growth in short interest in June. As of June 30th, there was short interest totalling 8,596,290 shares, a growth of 37.5% from the June 15th total of 6,251,775 shares. Currently, 19.7% of the shares of the stock are short sold. Based on an average daily trading volume, of 528,975 shares, the short-interest ratio is currently 16.3 days.
Shares of United Therapeutics Corporation (NASDAQ UTHR) opened at 129.96 on Wednesday. The stock has a market capitalization of $5.86 billion, a price-to-earnings ratio of 9.13 and a beta of 1.52. United Therapeutics Corporation has a 12 month low of $110.72 and a 12 month high of $169.89. The firm’s 50 day moving average is $129.77 and its 200 day moving average is $137.45.
United Therapeutics Corporation (NASDAQ:UTHR) last issued its quarterly earnings results on Wednesday, April 26th. The biotechnology company reported $3.89 EPS for the quarter, beating analysts’ consensus estimates of $3.12 by $0.77. The company had revenue of $370.50 million for the quarter, compared to analyst estimates of $399.59 million. United Therapeutics Corporation had a return on equity of 34.74% and a net margin of 41.04%. The company’s quarterly revenue was up .4% compared to the same quarter last year. During the same period last year, the company earned $3.02 earnings per share. On average, equities analysts predict that United Therapeutics Corporation will post $14.46 earnings per share for the current fiscal year.
United Therapeutics Corporation declared that its Board of Directors has authorized a stock buyback plan on Thursday, April 27th that permits the company to buyback $250.00 million in shares. This buyback authorization permits the biotechnology company to reacquire up to 4.6% of its shares through open market purchases. Shares buyback plans are typically a sign that the company’s leadership believes its stock is undervalued.
UTHR has been the subject of several recent analyst reports. ValuEngine lowered shares of United Therapeutics Corporation from a “strong-buy” rating to a “buy” rating in a research note on Friday, June 2nd. BidaskClub upgraded shares of United Therapeutics Corporation from a “sell” rating to a “hold” rating in a research note on Friday, June 16th. Credit Suisse Group reissued an “underperform” rating and set a $120.00 target price on shares of United Therapeutics Corporation in a research report on Monday, April 3rd. J P Morgan Chase & Co set a $125.00 target price on shares of United Therapeutics Corporation and gave the stock a “hold” rating in a research report on Tuesday, April 11th. Finally, Wedbush reaffirmed an “outperform” rating and issued a $229.00 price objective on shares of United Therapeutics Corporation in a report on Tuesday, April 4th. Five analysts have rated the stock with a sell rating, eight have given a hold rating, two have assigned a buy rating and one has issued a strong buy rating to the company’s stock. The company presently has a consensus rating of “Hold” and a consensus price target of $134.50.
In related news, CEO Martine A. Rothblatt sold 1,238 shares of United Therapeutics Corporation stock in a transaction dated Thursday, July 13th. The shares were sold at an average price of $130.44, for a total transaction of $161,484.72. Following the completion of the transaction, the chief executive officer now directly owns 1,378 shares of the company’s stock, valued at approximately $179,746.32. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Martine A. Rothblatt sold 1,262 shares of United Therapeutics Corporation stock in a transaction dated Thursday, April 27th. The stock was sold at an average price of $120.78, for a total transaction of $152,424.36. Following the transaction, the chief executive officer now directly owns 1,402 shares of the company’s stock, valued at $169,333.56. The disclosure for this sale can be found here. Insiders sold a total of 23,807 shares of company stock valued at $3,039,475 over the last three months. Corporate insiders own 7.80% of the company’s stock.
A number of hedge funds and other institutional investors have recently made changes to their positions in UTHR. Nomura Asset Management Co. Ltd. increased its stake in United Therapeutics Corporation by 0.3% in the first quarter. Nomura Asset Management Co. Ltd. now owns 12,646 shares of the biotechnology company’s stock worth $1,712,000 after buying an additional 40 shares during the period. Fisher Asset Management LLC increased its position in shares of United Therapeutics Corporation by 1.4% in the second quarter. Fisher Asset Management LLC now owns 3,169 shares of the biotechnology company’s stock worth $411,000 after buying an additional 45 shares during the last quarter. Argent Capital Management LLC increased its position in shares of United Therapeutics Corporation by 2.4% in the first quarter. Argent Capital Management LLC now owns 2,530 shares of the biotechnology company’s stock worth $343,000 after buying an additional 60 shares during the last quarter. Ladenburg Thalmann Financial Services Inc. increased its position in shares of United Therapeutics Corporation by 11.3% in the fourth quarter. Ladenburg Thalmann Financial Services Inc. now owns 717 shares of the biotechnology company’s stock worth $104,000 after buying an additional 73 shares during the last quarter. Finally, PNC Financial Services Group Inc. increased its position in shares of United Therapeutics Corporation by 4.8% in the first quarter. PNC Financial Services Group Inc. now owns 2,092 shares of the biotechnology company’s stock worth $284,000 after buying an additional 95 shares during the last quarter.
COPYRIGHT VIOLATION NOTICE: “United Therapeutics Corporation (NASDAQ:UTHR) Short Interest Up 37.5% in June” was first published by StockNewsTimes and is owned by of StockNewsTimes. If you are reading this piece of content on another publication, it was illegally copied and reposted in violation of U.S. and international copyright & trademark laws. The legal version of this piece of content can be accessed at https://stocknewstimes.com/2017/07/19/united-therapeutics-corporation-nasdaquthr-short-interest-up-37-5-in-june.html.
United Therapeutics Corporation Company Profile
United Therapeutics Corporation is a biotechnology company. The Company is focused on the development and commercialization of products for the treatment of chronic and life-threatening conditions. The Company markets and sells four commercial therapies in the United States to treat pulmonary arterial hypertension (PAH): Remodulin (treprostinil) Injection; Tyvaso (treprostinil) Inhalation Solution (Tyvaso); Orenitram (treprostinil) Extended-Release Tablets (Orenitram); and Adcirca (tadalafil) Tablets (Adcirca).
Receive News & Ratings for United Therapeutics Corporation Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics Corporation and related companies with MarketBeat.com's FREE daily email newsletter.
